{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:16:56Z","timestamp":1790745416707,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013140","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000}}],"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["101897 BuruliNox TMA 2016 SF-1509"],"award-info":[{"award-number":["101897 BuruliNox TMA 2016 SF-1509"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["461611374"],"award-info":[{"award-number":["461611374"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["461611374"],"award-info":[{"award-number":["461611374"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["461611374"],"award-info":[{"award-number":["461611374"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["101897 BuruliNox TMA 2016 SF-1509"],"award-info":[{"award-number":["101897 BuruliNox TMA 2016 SF-1509"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["461611374"],"award-info":[{"award-number":["461611374"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec018\">\n<jats:title>Background<\/jats:title>\n<jats:p>We previously showed that the presence of secondary bacteria influences clinical outcome in Buruli ulcer (BU) patients. Despite this, there is limited data on the antimicrobial resistance of these bacterial isolates within BU lesions. To gain understanding of antimicrobial resistance in BU, we longitudinally profiled antimicrobial resistance in frequently isolated bacterial organisms from these lesions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec019\">\n<jats:title>Methodology\/Principal findings<\/jats:title>\n<jats:p>Between August 2021 and June 2024, we assessed the antimicrobial resistance of pathogenic bacterial isolates within lesions of laboratory confirmed BU patients in Ghana. Wound swabs were collected longitudinally. The bacteria were identified and their antibiotic susceptibility tested using the VITEK 2 compact. Of the 166 bacterial isolates, eight bacterial species were identified comprising 56.9% Gram negative bacilli and 43.1% Gram positive cocci. We found the presence of pathogenic bacteria with varying levels of resistance to commonly used antibiotics in BU lesions before, during and after BU-specific antibiotic treatment. At baseline, all bacterial isolates were resistant to at least one antibiotic. Notably, Extended Spectrum Beta-Lactamase (ESBL) production was detected in 30% of Gram-negative isolates tested while 50% of the <jats:italic>Staphylococcus aureus<\/jats:italic> isolates tested positive for MRSA. There was a decline in the ESBL positive isolates over time (from 30% to 0) whereas MRSA positive isolates increased after treatment in the lesions (from 50% to 60%).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Conclusions and significance<\/jats:title>\n<jats:p>Results from this study highlight a concerning prevalence of antimicrobial resistant bacteria, including multi drug resistant (MDR), ESBL-positive and Methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) pathogens, in Buruli ulcer lesions. These findings underscore the urgent need for the development of integrated guidelines to guide surveillance and treatment of secondary bacterial infections to further improve outcomes in BU.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pntd.0013140","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:38:46Z","timestamp":1748367526000},"page":"e0013140","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana"],"prefix":"10.1371","volume":"19","author":[{"given":"Nancy","family":"Ackam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity Wiafe","family":"Akenten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail Opoku","family":"Boadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Agbanyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabiru Mohammed","family":"Abass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Amofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Azabire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustina","family":"Sylverken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwasi","family":"Obiri-Danso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wansbrough-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Thye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4642-789X","authenticated-orcid":true,"given":"Yaw Ampem","family":"Amoako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Odame","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"13","key":"pntd.0013140.ref001","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3390\/healthcare11131946","article-title":"Antimicrobial Resistance: A Growing Serious Threat for Global Public Health","volume":"11","author":"MA Salam","year":"2023","journal-title":"Healthcare (Basel)"},{"issue":"11","key":"pntd.0013140.ref002","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/ijerph16111925","article-title":"Emerging Resistance of Neglected Tropical Diseases: A Scoping Review of the Literature","volume":"16","author":"FT Akinsolu","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"pntd.0013140.ref003","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005456","article-title":"Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?","volume":"6","author":"HC Turner","year":"2021","journal-title":"BMJ Glob Health"},{"key":"pntd.0013140.ref004","volume-title":"Neglected tropical diseases and One Health: gearing up against antimicrobial resistance to secure the safety of future generations, meeting report","author":"WHO","year":"2020"},{"key":"pntd.0013140.ref005","author":"J O\u2019neill","year":"2016"},{"issue":"6","key":"pntd.0013140.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009454","article-title":"Caregiver burden in Buruli ulcer disease: Evidence from Ghana","volume":"15","author":"YA Amoako","year":"2021","journal-title":"PLoS Neglected Tropical Diseases"},{"issue":"1","key":"pntd.0013140.ref007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-021-00891-8","article-title":"Mental health and quality of life burden in Buruli ulcer disease patients in Ghana","volume":"10","author":"YA Amoako","year":"2021","journal-title":"Infectious Diseases of Poverty"},{"issue":"4","key":"pntd.0013140.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0012093","article-title":"Stigma experiences, effects and coping among individuals affected by Buruli ulcer and yaws in Ghana","volume":"18","author":"RD Tuwor","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013140.ref009","author":"WHO","year":"2019"},{"issue":"11","key":"pntd.0013140.ref010","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/AAC.00175-07","article-title":"Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)","volume":"51","author":"A Chauty","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0013140.ref011","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3201\/eid1104.041000","article-title":"Buruli ulcer recurrence, Benin","volume":"11","author":"M Debacker","year":"2005","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"pntd.0013140.ref012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00430-009-0109-6","article-title":"Buruli ulcer disease: prospects for a vaccine","volume":"198","author":"K Huygen","year":"2009","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"pntd.0013140.ref013","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17512433.2020.1752663","article-title":"Pharmacologic management of Mycobacterium ulcerans infection","volume":"13","author":"TS Van Der Werf","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"pntd.0013140.ref014","article-title":"Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)","volume":"8","author":"RR Yotsu","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"pntd.0013140.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005695","article-title":"Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase\/IS 2404 qPCR assay","volume":"11","author":"M Sarpong-Duah","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0013140.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007689","article-title":"Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load","volume":"13","author":"M Frimpong","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013140.ref017","doi-asserted-by":"crossref","first-page":"100468","DOI":"10.1016\/j.jctube.2024.100468","article-title":"Bacterial diversity in Buruli ulcer lesions in Ghana","volume":"36","author":"N Ackam","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"pntd.0013140.ref018","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-030-11114-4_13","article-title":"Secondary Infection of Buruli Ulcer Lesions.","volume-title":"Buruli Ulcer: Mycobacterium Ulcerans Disease","author":"GS Kpeli","year":"2019"},{"issue":"1","key":"pntd.0013140.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002010","article-title":"Towards rational use of antibiotics for suspected secondary infections in Buruli ulcer patients","volume":"7","author":"YT Barogui","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013140.ref020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/bbrj.bbrj_37_17","article-title":"Longitudinal assessment of the bacterial burden of buruli ulcer wounds during treatment","volume":"1","author":"D Yeboah-Manu","year":"2017","journal-title":"Biomed Biotechnol Res J"},{"issue":"5","key":"pntd.0013140.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002191","article-title":"Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin","volume":"7","author":"D Yeboah-Manu","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0013140.ref022","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1590\/0037-8682-0404-2016","article-title":"Secondary bacterial isolates from previously untreated Buruli ulcer lesions and their antibiotic susceptibility patterns in Southern Nigeria","volume":"49","author":"MC Anyim","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"key":"pntd.0013140.ref023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nmni.2016.07.001","article-title":"Possible healthcare-associated transmission as a cause of secondary infection and population structure of Staphylococcus aureus isolates from two wound treatment centres in Ghana","volume":"13","author":"G Kpeli","year":"2016","journal-title":"New Microbes New Infect"},{"issue":"2","key":"pntd.0013140.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003421","article-title":"Genetic diversity of Staphylococcus aureus in Buruli ulcer","volume":"9","author":"NA Amissah","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0013140.ref025","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3047","article-title":"Genomic analysis of ST88 community-acquired methicillin resistant Staphylococcus aureus in Ghana","volume":"5","author":"G Kpeli","year":"2017","journal-title":"PeerJ"},{"issue":"5","key":"pntd.0013140.ref026","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01058-16","article-title":"Redefining the Chronic-Wound Microbiome: Fungal Communities Are Prevalent, Dynamic, and Associated with Delayed Healing","volume":"7","author":"L Kalan","year":"2016","journal-title":"mBio"},{"issue":"10325","key":"pntd.0013140.ref027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"issue":"20","key":"pntd.0013140.ref028","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"pntd.0013140.ref029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00005373-197602000-00002","article-title":"The quantitative swab culture and smear: A quick, simple method for determining the number of viable aerobic bacteria on open wounds","volume":"16","author":"NS Levine","year":"1976","journal-title":"J Trauma"},{"key":"pntd.0013140.ref030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/CWCMR.S85469","article-title":"Buruli ulcer: wound care and rehabilitation","volume":"3","author":"R Phillips","year":"2016","journal-title":"CWCMR"},{"issue":"9525","key":"pntd.0013140.ref031","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(06)68807-7","article-title":"Buruli ulcer: emerging from obscurity","volume":"367","author":"M Wansbrough-Jones","year":"2006","journal-title":"Lancet"},{"key":"pntd.0013140.ref032","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.envres.2018.11.040","article-title":"Human health risk assessment of antibiotic resistance associated with antibiotic residues in the environment: A review","volume":"169","author":"Y Ben","year":"2019","journal-title":"Environ Res"},{"issue":"10","key":"pntd.0013140.ref033","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/pathogens10101310","article-title":"Bacterial Antibiotic Resistance: The Most Critical Pathogens","volume":"10","author":"G Mancuso","year":"2021","journal-title":"Pathogens"},{"issue":"9715","key":"pntd.0013140.ref034","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(09)61962-0","article-title":"Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial","volume":"375","author":"WA Nienhuis","year":"2010","journal-title":"Lancet"},{"issue":"10232","key":"pntd.0013140.ref035","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"RO Phillips","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"pntd.0013140.ref036","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/AAC.02165-13","article-title":"Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease","volume":"58","author":"RO Phillips","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"pntd.0013140.ref037","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/AAC.00299-10","article-title":"Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease","volume":"54","author":"FS Sarfo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"pntd.0013140.ref038","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(14)70223-2","article-title":"Clinical epidemiology of laboratory-confirmed Buruli ulcer in Benin: a cohort study","volume":"2","author":"QB Vincent","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"9","key":"pntd.0013140.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004049","article-title":"Molecular Characterization of Staphylococcus aureus Isolates Transmitted between Patients with Buruli Ulcer","volume":"9","author":"NA Amissah","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0013140.ref040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jhin.2014.12.014","article-title":"Whole-genome sequencing in hierarchy with pulsed-field gel electrophoresis: the utility of this approach to establish possible sources of MRSA cross-transmission","volume":"90","author":"G Moore","year":"2015","journal-title":"J Hosp Infect"},{"key":"pntd.0013140.ref041","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3310\/nihropenres.13332.2","article-title":"Buruli-RifDACC: Evaluation of the efficacy and cost-effectiveness of high-dose versus standard-dose rifampicin on outcomes in Mycobacteriumulcerans disease, a protocol for a randomised controlled trial in Ghana","volume":"2","author":"YA Amoako","year":"2023","journal-title":"NIHR Open Res"},{"issue":"8","key":"pntd.0013140.ref042","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1128\/AAC.48.8.2866-2870.2004","article-title":"Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides","volume":"48","author":"R Phillips","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0013140.ref043","first-page":"215","article-title":"Resistance to antimicrobial drugs in Ghana","volume":"4","author":"MJ Newman","year":"2011","journal-title":"Infect Drug Resist"},{"issue":"7","key":"pntd.0013140.ref044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181072","article-title":"Epidemiology of Staphylococcus aureus in a burn unit of a tertiary care center in Ghana","volume":"12","author":"NA Amissah","year":"2017","journal-title":"PLoS One"},{"key":"pntd.0013140.ref045","doi-asserted-by":"crossref","first-page":"117094","DOI":"10.1016\/j.socscimed.2024.117094","article-title":"The role of economic factors in shaping and constituting the household burden of neglected tropical diseases of the skin: Qualitative findings from Ghana and Ethiopia","volume":"356","author":"Y Hailemichael","year":"2024","journal-title":"Soc Sci Med"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013140","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T18:17:00Z","timestamp":1749061020000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013140"}},"subtitle":[],"editor":[{"given":"Paul J.","family":"Converse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013140","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pntd.0013140","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}